Research Paper Volume 13, Issue 2 pp 2959—2981

A novel five-lncRNA signature panel improves high-risk survival prediction in patients with cholangiocarcinoma

Prognostic evaluation of the five-lncRNA signature in CCA patients in TCGA. (A) The survival status and duration of CCA patients; (B) LncRNA risk score distribution; the blue dashed line indicates dividing the patient into a low-risk group and a high-risk group with a median value as a cut off value. (C) Heatmap of five lncRNA expressions in CCA patients. (D) KM curves based on OS outcomes for risk cutoffs with a p-value of less than 0.01 for the log-rank test. (E) Time-dependent ROC curve analysis was predicted by five lncRNA for 3-year survival, and each was performed separately.

Figure 2. Prognostic evaluation of the five-lncRNA signature in CCA patients in TCGA. (A) The survival status and duration of CCA patients; (B) LncRNA risk score distribution; the blue dashed line indicates dividing the patient into a low-risk group and a high-risk group with a median value as a cut off value. (C) Heatmap of five lncRNA expressions in CCA patients. (D) KM curves based on OS outcomes for risk cutoffs with a p-value of less than 0.01 for the log-rank test. (E) Time-dependent ROC curve analysis was predicted by five lncRNA for 3-year survival, and each was performed separately.